Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Molecular Subtyping and Immunotherapy in Fertility-Preserving Approaches for Endometrial Cancer: Challenges and Prospects

  • By

  • Jing Li

  • Shixiang Dong

  • Dongdong Hu

  • Wen Feng

  • July 9, 2026

Share

  • 1

    Endometrial cancer is a prevalent malignancy in women, with approximately 417,000 new cases and 97,000 deaths reported in 2020.

  • 2

    Fertility-sparing treatment (FST) allows young women with endometrial cancer to preserve fertility before standard treatment.

  • 3

    Molecular classification reveals that patients with POLE mutations have better prognosis, while those with dMMR face higher recurrence rates.

  • 4

    Immune checkpoint inhibitors (ICIs) show potential in enhancing outcomes for patients undergoing fertility-sparing treatment for endometrial cancer.

  • 5

    Hysteroscopic resection combined with progestin therapy is currently the most effective method for fertility-sparing treatment.

Original Source(s)

Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges

  • by Jing Li, Shixiang Dong, Dongdong Hu, Wen Feng

  • July 9, 2026

Related Content

Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report

Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis